Aptose Biosciences
APTO
APTO was delisted on the 1st of April, 2025.
56 hedge funds and large institutions have $174M invested in Aptose Biosciences in 2019 Q4 according to their latest regulatory filings, with 34 funds opening new positions, 11 increasing their positions, 7 reducing their positions, and 9 closing their positions.
540% more capital inflows, than outflows
Capital inflows: $56.8M | Capital outflows: $8.88M
278% more first-time investments, than exits
New positions opened: 34 | Existing positions closed: 9
81% more funds holding
Funds holding: 31 → 56 (+25)
57% more repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 7
54% more call options, than puts
Call options by funds: $1.41M | Put options by funds: $918K
15.88% more ownership
Funds ownership: 25.62% → 41.5% (+16%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Consonance Capital Management
New York
|
+$13.8M |
| 2 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$9.7M |
| 3 |
Nantahala Capital Management
New Canaan,
Connecticut
|
+$5.17M |
| 4 |
OrbiMed
New York
|
+$3.33M |
| 5 |
Driehaus Capital Management
Chicago,
Illinois
|
+$2.81M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$4.14M |
| 2 |
Man Group
London,
United Kingdom
|
-$4.02M |
| 3 |
Creative Planning
Overland Park,
Kansas
|
-$156K |
| 4 |
Sanders Morris Harris
Houston,
Texas
|
-$136K |
| 5 |
JP Morgan Chase
New York
|
-$133K |
APTO Hedge Fund Activity: Q4 2019 in Review
56 of the 5,095 institutional investors tracked by Wall St. Rank reported a position in Aptose Biosciences (APTO) for Q4 2019, worth a combined $174M — up 489% from $29.6M a quarter earlier.
Buyers outnumbered sellers: 34 funds opened new APTO positions and 9 closed out — a net gain of 25 holders — while 11 added to existing stakes and 7 trimmed.
The largest buyer was Consonance Capital Management, opening a new position worth an estimated $13.8M. The largest seller was Point72 Asset Management, cutting an estimated $4.14M.
- 56 institutional investors held Aptose Biosciences (APTO) as of Q4 2019, up from 31 in Q3 2019.
- Funds reported $174M of Aptose Biosciences stock for Q4 2019, up 489% quarter-over-quarter.
- 34 funds opened new Aptose Biosciences positions in Q4 2019 and 9 closed out, a net change of +25 holders.
- The largest Aptose Biosciences buyer in Q4 2019 was Consonance Capital Management, an estimated $13.8M added.
- The largest Aptose Biosciences seller in Q4 2019 was Point72 Asset Management, an estimated $4.14M sold.
Based on aggregated 13F filings for Q4 2019.